CA1250525A - Composition for the relief of menstrual symptoms - Google Patents
Composition for the relief of menstrual symptomsInfo
- Publication number
- CA1250525A CA1250525A CA000471387A CA471387A CA1250525A CA 1250525 A CA1250525 A CA 1250525A CA 000471387 A CA000471387 A CA 000471387A CA 471387 A CA471387 A CA 471387A CA 1250525 A CA1250525 A CA 1250525A
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- composition according
- calcium
- composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000002175 menstrual effect Effects 0.000 title claims abstract description 10
- 208000024891 symptom Diseases 0.000 title description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 25
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 22
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 19
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 19
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 19
- 239000011710 vitamin D Substances 0.000 claims abstract description 19
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 19
- 229940046008 vitamin d Drugs 0.000 claims abstract description 19
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 16
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 11
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims abstract description 9
- 235000010376 calcium ascorbate Nutrition 0.000 claims abstract description 8
- 229940047036 calcium ascorbate Drugs 0.000 claims abstract description 8
- 239000011692 calcium ascorbate Substances 0.000 claims abstract description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 8
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims abstract description 8
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims abstract description 8
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims abstract description 8
- 235000021323 fish oil Nutrition 0.000 claims abstract description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 7
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 6
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 6
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 6
- 230000027758 ovulation cycle Effects 0.000 claims abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 27
- 239000011575 calcium Substances 0.000 claims description 27
- 229910052791 calcium Inorganic materials 0.000 claims description 27
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 229960003495 thiamine Drugs 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000011721 thiamine Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010013082 Discomfort Diseases 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000005906 menstruation Effects 0.000 abstract description 5
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- 206010016352 Feeling of relaxation Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 206010043268 Tension Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000738 kidney tubule Anatomy 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940077736 other combination of nutrients in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 235000011890 sandwich Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A non-toxic, non-allergenic composition that provides relief from menstrual stresses (experienced by females at puberty, during menstruation, and during psuedo menstrual cycles) wherein a single dose comprises the following: 5 000 I.U. of Vitamin D (fish oil source), 1 gram calcium carbonate, 400 mg magnesium hydroxide, 1 gram Vitamin C (calcium ascorbate), 1 gram pantothenic acid, 100 mg B6 (pyridoxine hydrochloride), 600 I.U.
Vitamin E (d-alpha tocopherol), and binders.
A non-toxic, non-allergenic composition that provides relief from menstrual stresses (experienced by females at puberty, during menstruation, and during psuedo menstrual cycles) wherein a single dose comprises the following: 5 000 I.U. of Vitamin D (fish oil source), 1 gram calcium carbonate, 400 mg magnesium hydroxide, 1 gram Vitamin C (calcium ascorbate), 1 gram pantothenic acid, 100 mg B6 (pyridoxine hydrochloride), 600 I.U.
Vitamin E (d-alpha tocopherol), and binders.
Description
-2-~ 2~
SPECIFICATION
Some females experience recurring severe menstrual symptoms much more so than do others. The usual treatment for menstrual symptoms (such as intestinal cramping) has been aspirin. tAspirin is a registered trade-mark used as a general pain reliever--acetylsalicylic acid.) Aspirin can alleviate pain, but it cannot cause calcium utilization to occur. Therefore, it is not effective for relieving insomnia, tremors, irribility, or tenseness. Aspirin can cause losses of calcium and B
vitamins, as well as accelerating the possibility of hemorrhaging due to losses of ascorbic acid.
In order to provide relief (without potentially harmful side effects) for pain caused by intestinal cramping, or relief from tremors, irribility, and insomnia tha-t occur due to menstruation, calcium mus-t be absorbed into the cells, followed by enzyme utilization of the calciurn.
Cell relaxa-tion can then occur. Nerve irritabili-ty caused by inadequate or poor enzyme ac-tivity to utilize the calcium, results in nervousness, tenseness, and irribility. Less calcium to the muscles results in cramps, tics, and/or spasms. Calcium assists nerve-impulse transportation.
Proper utilization of sufficient calcium can result in a reduction of nerve and muscle excitability.
Estrogen treatment deals successfully with mens-trual symptoms by causing effective absorb-tion calcium. Once the calcium has been absorbed by the cells, the hormone messenger, estrogen, tells (activates) the cell enzymes how to affectively utilize calcium. Because of this utilization, cellular relaxation occurs. Menstrual sympstoms (such as intestinal cramping, irritability, nervousness, insomnia) disappear.
~2~
Estrogen is normally produced by the ovaries. Blood calcium levels start dropping a few days before menstruation and are low during menstruation. The blood calcium levels are sometimes low even ten days prior to menstruation. This drop in blood calcium levels is due to a less active ovarian production oE estrogen; therefore, more calcium is lost in the urine and is not effectively utilized. Puberty estrogen production is not adequate. Menopause brings a cessation of estrogen production from -the ovaries. Even if calcium supplementation is taken, it is still not the answer because~the adrenal hormones can break down the bones to supply all the calcium the body needs.
The answer is to produce the same effect as estrogen has--to allow effective calcium utilization and effective cellular enzyme utilization--but to do so with no side effects that estrogen therapy can cause. Estrogen has caused cancer in laboratory animals. Estrogen therapy causes a -tremendous increase in the need for Vitamin E (D alpha tocopherol acetate). Estrogen therapy can cause dormant cancer cells to become active. A lack of Vitamin E can cause calcifica-tion of -the soft tissues such as in the liver, brain, muscles, blood vessel walls.
Tissue damage shown by scarring and/or pigmentation can occur anywhere in the body but is noticeable on the skin as brown spots, common at menopause in women taking estrogen therapy.
This formula applied for herein reacts similarily -to estrogen by increasing the blood calcium levels, allowing great significant intestinal calcium absorption and reabsorption through the kidney tubules.
Kidneys are capable of reabsorbing over 90 percent of -the calcium from the kidney tubules, but Vitamin D is critical to allow this absorption to occur. The cells select the quantity of calcium needed. The formula provides optimum enzyme utilization to occur; therefore cellular relaxa-tion occurs. Mens-trual symptoms dissappear. Adequate Vitamin D
amounts must be present to cause enzyme activity to effec-tively utilize ' ~
calcium. The amount of Vitamin D provided for in the formula prevents magnesium loss Erom the kidneys. Magnesium is necessary to enhance the effectiveness of calcium utilization.
No other combinations of nutrients can provide the same effec-tive calcium utilization that Vitamin D can. Vitamin D toxicity is prevented by the use of fish-oil type Vitamin D, not the highly toxic Vitamin D synthetically produced when vegetable oils are exposed to ultraviolet light. (They are called synthetic Vitamin D, irradiated ergosterol.) This toxicity is also prevented by the addition of Vitamins C and E. Addi-tionally, the formula provides for Vitamin E, B6 (pyridoxine hydrochloride), magnesium to prevent calcification of tissues.
People living in the subtropics normally have comparatively high blood levels of Vitamin D without any dietary supplementation.
In order for most North Americans to reach this level, a dietary supplement of approximately 5,000 I.U. Vitamin D (from fish oils) would have to be consumer on a daily basis, perhaps for several mon-ths. If the type of Vi-tamin D taken were synthe-tic (irradiated ergosterol), ~hcJ~phc ~`~5 toxicity would likely occur along wi-th calcium and-~h~h~r-~s losses.
Vitamin D is included in the formula to also permit the excretion of excess phosphorus and sodium, thereby providing for better calcium-absorptinn. Pantothenic acid is included for -the excretion of excess sodium.
The following ingredients constitute, in these proportions, a single dose, a preferred composition: 5,000 I.U. Vitamin D; 1 gram calcium carbonate; ~00 mg magnesium hydroxide; 1 gram Vitamin C (ascorbic acid)j in the form calcium ascorbate so tha-t it will be acid-free or ph neutral; 100 mg B6; 1 gram pantothenic acid; 600 I.U. Vitamin E (d-alpha tocopherol). (The Vitamin B6 is pyridoxine hydrochloride, and the pantothenic acid is calcium d-pan-tothenate.) In addition, the use of 100 mg Vitamin B2 (riboflavin) and 100 mg Vitamin B1 (thiamine) is optional, and compositions can be used without these ingredients.
` _5_ ~5~5~
Do not take the formula on an empty stomach or with just a glass of water. The best time to take the formula is when eating a meal or just after completing the meal. If taken between meals, other food containing some fat (such as cheese, milk, sandwich) should be consumed. Sucrose (table sugar) and products containing sucrose should not be consumed at the same time as the formula because sucrose tends to , stimulate the production of alkaline digestive juices so rapidly that J~Jso/c~/e calcium in the formula could become ~oluable-before it can reach the blood, thereby preventing optimum effectiveness of the composition. It is advisable to take the composition a day before the onslaught of the menstrual period, and as necessary after the period (e.g., 3 to 4 days).
If symptoms tend to be severe, a second, smaller dose at bed-time is recommended. This smaller, abbreviated dose, would consist of 750 mg calcium carbonate, 345 mg magnesium hydroxide, 500 mg acid-free Vitamin C
(ascorblc acid in calcium ascorbate form), 50 mg B6 (pyridoxine hydrochloride), 1 gram pantothenic acid, 1 000 I.U. fish oil Vitamin D, 200 I.U. Vitamin E (d-alpha tocopherol), plus an optional 50 mg Vi-tamin Bl (-thiamine) and an optional 50 mg Vitamin B2 (riboElavin). The calcium carbonate and -the magnesium hydroxide should be in tablet form and could probably be combined into one tablet. If preferred, the B Vitamins (pantothenic acid, B21 Bl, B6) and the Vitamin C could be combined into one tablet.
The range of amounts of the above materials which can be used in the combination will be apparent to one skilled in the art bu-t for clarity it is stated that the amount of Vitamin D (fish oil source) can lie in the range of 5 000 to 6 000 I.U. in capsule form; the amount of calcium carbonate can lie in the range of 750 mg to 1 gram in tablet form; the amount of magnesium hydroxide can lie in the range of 300 to 4~5 mg in tablet form; the amount of Vitamin C (calcium ascorbate) can lie in the range of 500 mg to 4 grams; the amount of Vitamin B6 (pyridoxine hydrochloride) can lie in the range of 50 to 250 mg; the amount of pantothenic acid can lie in the range of 1 gram to 4 grams; -the amount of Vitamin E (d-alpha - 6 ~ 5~15;25 P 1660-1 CA
tocopherol) can li2 in the range of 400 I.U. to 1 200 I.U. in capsule form; the amount of Vitamin Bl (thiamine) can lie in the range of 50 to 100 mg; the amount of Vitamin B2 (riboflavin) can lie in the range of 50 to 100 mg. f3inders of a convention form (sugar free) can be used, as will be apparent to one skilled 5 in the art.
SPECIFICATION
Some females experience recurring severe menstrual symptoms much more so than do others. The usual treatment for menstrual symptoms (such as intestinal cramping) has been aspirin. tAspirin is a registered trade-mark used as a general pain reliever--acetylsalicylic acid.) Aspirin can alleviate pain, but it cannot cause calcium utilization to occur. Therefore, it is not effective for relieving insomnia, tremors, irribility, or tenseness. Aspirin can cause losses of calcium and B
vitamins, as well as accelerating the possibility of hemorrhaging due to losses of ascorbic acid.
In order to provide relief (without potentially harmful side effects) for pain caused by intestinal cramping, or relief from tremors, irribility, and insomnia tha-t occur due to menstruation, calcium mus-t be absorbed into the cells, followed by enzyme utilization of the calciurn.
Cell relaxa-tion can then occur. Nerve irritabili-ty caused by inadequate or poor enzyme ac-tivity to utilize the calcium, results in nervousness, tenseness, and irribility. Less calcium to the muscles results in cramps, tics, and/or spasms. Calcium assists nerve-impulse transportation.
Proper utilization of sufficient calcium can result in a reduction of nerve and muscle excitability.
Estrogen treatment deals successfully with mens-trual symptoms by causing effective absorb-tion calcium. Once the calcium has been absorbed by the cells, the hormone messenger, estrogen, tells (activates) the cell enzymes how to affectively utilize calcium. Because of this utilization, cellular relaxation occurs. Menstrual sympstoms (such as intestinal cramping, irritability, nervousness, insomnia) disappear.
~2~
Estrogen is normally produced by the ovaries. Blood calcium levels start dropping a few days before menstruation and are low during menstruation. The blood calcium levels are sometimes low even ten days prior to menstruation. This drop in blood calcium levels is due to a less active ovarian production oE estrogen; therefore, more calcium is lost in the urine and is not effectively utilized. Puberty estrogen production is not adequate. Menopause brings a cessation of estrogen production from -the ovaries. Even if calcium supplementation is taken, it is still not the answer because~the adrenal hormones can break down the bones to supply all the calcium the body needs.
The answer is to produce the same effect as estrogen has--to allow effective calcium utilization and effective cellular enzyme utilization--but to do so with no side effects that estrogen therapy can cause. Estrogen has caused cancer in laboratory animals. Estrogen therapy causes a -tremendous increase in the need for Vitamin E (D alpha tocopherol acetate). Estrogen therapy can cause dormant cancer cells to become active. A lack of Vitamin E can cause calcifica-tion of -the soft tissues such as in the liver, brain, muscles, blood vessel walls.
Tissue damage shown by scarring and/or pigmentation can occur anywhere in the body but is noticeable on the skin as brown spots, common at menopause in women taking estrogen therapy.
This formula applied for herein reacts similarily -to estrogen by increasing the blood calcium levels, allowing great significant intestinal calcium absorption and reabsorption through the kidney tubules.
Kidneys are capable of reabsorbing over 90 percent of -the calcium from the kidney tubules, but Vitamin D is critical to allow this absorption to occur. The cells select the quantity of calcium needed. The formula provides optimum enzyme utilization to occur; therefore cellular relaxa-tion occurs. Mens-trual symptoms dissappear. Adequate Vitamin D
amounts must be present to cause enzyme activity to effec-tively utilize ' ~
calcium. The amount of Vitamin D provided for in the formula prevents magnesium loss Erom the kidneys. Magnesium is necessary to enhance the effectiveness of calcium utilization.
No other combinations of nutrients can provide the same effec-tive calcium utilization that Vitamin D can. Vitamin D toxicity is prevented by the use of fish-oil type Vitamin D, not the highly toxic Vitamin D synthetically produced when vegetable oils are exposed to ultraviolet light. (They are called synthetic Vitamin D, irradiated ergosterol.) This toxicity is also prevented by the addition of Vitamins C and E. Addi-tionally, the formula provides for Vitamin E, B6 (pyridoxine hydrochloride), magnesium to prevent calcification of tissues.
People living in the subtropics normally have comparatively high blood levels of Vitamin D without any dietary supplementation.
In order for most North Americans to reach this level, a dietary supplement of approximately 5,000 I.U. Vitamin D (from fish oils) would have to be consumer on a daily basis, perhaps for several mon-ths. If the type of Vi-tamin D taken were synthe-tic (irradiated ergosterol), ~hcJ~phc ~`~5 toxicity would likely occur along wi-th calcium and-~h~h~r-~s losses.
Vitamin D is included in the formula to also permit the excretion of excess phosphorus and sodium, thereby providing for better calcium-absorptinn. Pantothenic acid is included for -the excretion of excess sodium.
The following ingredients constitute, in these proportions, a single dose, a preferred composition: 5,000 I.U. Vitamin D; 1 gram calcium carbonate; ~00 mg magnesium hydroxide; 1 gram Vitamin C (ascorbic acid)j in the form calcium ascorbate so tha-t it will be acid-free or ph neutral; 100 mg B6; 1 gram pantothenic acid; 600 I.U. Vitamin E (d-alpha tocopherol). (The Vitamin B6 is pyridoxine hydrochloride, and the pantothenic acid is calcium d-pan-tothenate.) In addition, the use of 100 mg Vitamin B2 (riboflavin) and 100 mg Vitamin B1 (thiamine) is optional, and compositions can be used without these ingredients.
` _5_ ~5~5~
Do not take the formula on an empty stomach or with just a glass of water. The best time to take the formula is when eating a meal or just after completing the meal. If taken between meals, other food containing some fat (such as cheese, milk, sandwich) should be consumed. Sucrose (table sugar) and products containing sucrose should not be consumed at the same time as the formula because sucrose tends to , stimulate the production of alkaline digestive juices so rapidly that J~Jso/c~/e calcium in the formula could become ~oluable-before it can reach the blood, thereby preventing optimum effectiveness of the composition. It is advisable to take the composition a day before the onslaught of the menstrual period, and as necessary after the period (e.g., 3 to 4 days).
If symptoms tend to be severe, a second, smaller dose at bed-time is recommended. This smaller, abbreviated dose, would consist of 750 mg calcium carbonate, 345 mg magnesium hydroxide, 500 mg acid-free Vitamin C
(ascorblc acid in calcium ascorbate form), 50 mg B6 (pyridoxine hydrochloride), 1 gram pantothenic acid, 1 000 I.U. fish oil Vitamin D, 200 I.U. Vitamin E (d-alpha tocopherol), plus an optional 50 mg Vi-tamin Bl (-thiamine) and an optional 50 mg Vitamin B2 (riboElavin). The calcium carbonate and -the magnesium hydroxide should be in tablet form and could probably be combined into one tablet. If preferred, the B Vitamins (pantothenic acid, B21 Bl, B6) and the Vitamin C could be combined into one tablet.
The range of amounts of the above materials which can be used in the combination will be apparent to one skilled in the art bu-t for clarity it is stated that the amount of Vitamin D (fish oil source) can lie in the range of 5 000 to 6 000 I.U. in capsule form; the amount of calcium carbonate can lie in the range of 750 mg to 1 gram in tablet form; the amount of magnesium hydroxide can lie in the range of 300 to 4~5 mg in tablet form; the amount of Vitamin C (calcium ascorbate) can lie in the range of 500 mg to 4 grams; the amount of Vitamin B6 (pyridoxine hydrochloride) can lie in the range of 50 to 250 mg; the amount of pantothenic acid can lie in the range of 1 gram to 4 grams; -the amount of Vitamin E (d-alpha - 6 ~ 5~15;25 P 1660-1 CA
tocopherol) can li2 in the range of 400 I.U. to 1 200 I.U. in capsule form; the amount of Vitamin Bl (thiamine) can lie in the range of 50 to 100 mg; the amount of Vitamin B2 (riboflavin) can lie in the range of 50 to 100 mg. f3inders of a convention form (sugar free) can be used, as will be apparent to one skilled 5 in the art.
Claims (16)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A composition for the relief of menstrual cramping pain comprising .75 to 1 g of calcium carbonate .3 to .4 g magnesium hydroxide .5 to 4 g of Vitamin C as calcium ascorbate 1 to 4 g of pantothenic acid .05 to .25 g of Vitamin B6 (pyridoxine hydrochloride) 3,000 to 6,000 I.U.Vitamin D from a fish oil source, and 400 to 1,200 I.U.Vitamin E (d-alpha tocopherol).
2. A composition according to Claim 1, wherein the amount of Vitamin D lies in the range of 4,000 to 5,000 I.U.
3. A composition according to Claim 1, wherein the amount of Vitamin C (calcium ascorbate) lies in the range of .5 to 1 g.
4. A composition according to Claim 1, wherein the amount of pantothenic acid is about 1 g.
5. A composition according to Claim 1, wherein the amount of Vitamin B6 (pyridoxine hydrochloride) lies in the range of 0.2 to 0.25 g.
6. A composition according to Claim 1, wherein the amount of Vitamin E (d-alpha tocopherol) is about 600 I.U.
7. A composition according to Claim 1 wherein said first group of constituents further includes about .1 g of Vitamin B1 (thiamine).
8. A composition according to Claim 1 or 7, wherein said first group of constituents further includes about .1 g of Vitamin B2 (riboflavin).
9. A composition according to Claim 1, wherein the Vitamin C is in calcium ascorbate form.
10. A composition as defined in Claim 1, 2 or 3 further including a pharmaceutically acceptable carrier therefor, wherein said carrier is sucrose free.
11. A composition for the relief of menstrual cramping pain and other discomforts caused by the menstrual cycle wherein a single dose comprises:
4,000 to 5,000 I.U. Vitamin D (Fish oil source) .75 to 1 g of calcium carbonate from .3 to .4 g of magnesium hydroxide from .5 to 1 g of Vitamin C
from 1 to 4 g of pantothenic acid from .05 to .1 g of Vitamin B6 (pyridoxine hydrochloride) 400 to 600 I.U. Vitamin E (d-alpha tocopherol).
4,000 to 5,000 I.U. Vitamin D (Fish oil source) .75 to 1 g of calcium carbonate from .3 to .4 g of magnesium hydroxide from .5 to 1 g of Vitamin C
from 1 to 4 g of pantothenic acid from .05 to .1 g of Vitamin B6 (pyridoxine hydrochloride) 400 to 600 I.U. Vitamin E (d-alpha tocopherol).
12. A composition according to Claim 11, further including .05 to .1 g of Vitamin B1 (thiamine).
13. A composition according to Claim 11, further including .05 to .1 g of Vitamin B2 (riboflavin)
14. A composition acording to Claim 11, 12 or 13, wherein said Vitamin C is in the form of calcium ascorbate.
15. A composition according to Claim 11, 12 or 13, further comprising a sucrose free pharmaceutically acceptable carrier therefor.
16. A composition for the relief of menstrual cramping pain comprising in admixture a pharmaceutically acceptable source of calcium, a pharmaceutically acceptable source of magnesium and fish oil source vitamin D, wherein a single dose form thereof comprises from about 0.75 g of calcium carbonate, from about 0.3 g of magnesium hydroxide, about 0.5 g acid free Vitamin C (ascorbic acid in the form of calcium ascorbate) about 0.05 g Vitamin B6, about 1 g Pantothenic acid about 1,000 I.U. of said Vitamin D, and about 200 I.U. of Vitamin E.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000471387A CA1250525A (en) | 1985-01-03 | 1985-01-03 | Composition for the relief of menstrual symptoms |
| GB8529812A GB2169202B (en) | 1985-01-03 | 1985-12-04 | Composition for the relief of menstrual symptoms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000471387A CA1250525A (en) | 1985-01-03 | 1985-01-03 | Composition for the relief of menstrual symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1250525A true CA1250525A (en) | 1989-02-28 |
Family
ID=4129506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000471387A Expired CA1250525A (en) | 1985-01-03 | 1985-01-03 | Composition for the relief of menstrual symptoms |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA1250525A (en) |
| GB (1) | GB2169202B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
| CA2144728C (en) * | 1992-09-15 | 2005-04-26 | Susan Thys-Jacobs | Method of treating premenstrual syndrome symptomatology with vitamin d or vitamin d and calcium |
| US5932226A (en) * | 1994-10-03 | 1999-08-03 | Harry M. Weiss | Method and kit for determining the optimum dosage level of physiologically useful substances |
| EP1661575A1 (en) * | 2004-11-26 | 2006-05-31 | ZAMBON GROUP S.p.A. | Use of magnesium in the treatment of disorders related to hormonal variations in women |
| US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| BR102013013564A2 (en) * | 2013-05-31 | 2015-07-07 | Ems Sa | Composition for the treatment or reduction of symptoms related to premenstrual tension (tpm), premenstrual dysphoric disorder (tdpm), premenopause, menopause or female hormonal disorders, pharmaceutical form containing said composition, process for producing said pharmaceutical form and use of said composition |
| IT202000003964A1 (en) | 2020-02-26 | 2021-08-26 | Umberto Cornelli | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSMENORREA AND / OR PREMESTRUAL SYNDROME |
-
1985
- 1985-01-03 CA CA000471387A patent/CA1250525A/en not_active Expired
- 1985-12-04 GB GB8529812A patent/GB2169202B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB2169202A (en) | 1986-07-09 |
| GB2169202B (en) | 1989-10-18 |
| GB8529812D0 (en) | 1986-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Monsen | Iron nutrition and absorption: dietary factors which impact iron bioavailability | |
| Emmett et al. | Calcium acetate control of serum phosphorus in hemodialysis patients | |
| Minich et al. | Acid-alkaline balance: role in chronic disease and detoxification | |
| US5626883A (en) | Ascorbic acid compositions providing enhanced human immune system activity | |
| US7887847B2 (en) | Nutritional supplement for treatment of ocular diseases | |
| Rastogi et al. | Selenium and lead: mutual detoxifying effects | |
| US8309081B2 (en) | Composition and method for treatment of bruising | |
| CA1250525A (en) | Composition for the relief of menstrual symptoms | |
| IE53147B1 (en) | Method for preventing parturient paresis in dairy cattle | |
| US20060210650A1 (en) | Supplemental dietary composition for promoting weight loss | |
| US5849337A (en) | Method of enhancing magnesium absorption and prevention of atherosclerosis | |
| US20060105033A1 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
| US20090062231A1 (en) | Appetite Suppressant Composition and Method of Appetite Suppression | |
| CA2124204A1 (en) | Composition and method for reducing free radical cellular oxidative stress in warm-blooded animals | |
| US6093423A (en) | Reduced absorption of fatty acids | |
| Świerk et al. | Effect of increased intake of concentrates and sodium butyrate supplementation on reticulorumen macroanatomy and reticulorumen fermentation in growing rams | |
| CA2427681A1 (en) | Dietary composition containing conjugated linoleic acid and calcium for improved health | |
| Giovannetti | Low-protein diets for chronic renal failure | |
| EP3693020A1 (en) | Potassium enriched topical formulations for pain relief and sleep aid | |
| WO2000054792A1 (en) | Drugs, foods, drinks and feeds containing cocoa component | |
| Zaleha et al. | The supplementation of levothyroxine among indigenous people in endemic goitre areas: The impact of therapy | |
| US7605145B2 (en) | Micronutrient formulations for treatment of diabetes mellitus | |
| Nielsen | Genetic Makeup on the Signs of Copper Deficiency in Rats | |
| Ratnoff et al. | Hepatic Damage in Rats Fed Human Foodstuffs. | |
| CA2517537A1 (en) | Potassium taurate bicarbonate and ascorbate complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |